Browse

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

DC Field Value Language
dc.contributor.authorKim, Hwi Young-
dc.contributor.authorLee, Dong Hyeon-
dc.contributor.authorLee, Jeong-Hoon-
dc.contributor.authorCho, Young Youn-
dc.contributor.authorCho, Eun Ju-
dc.contributor.authorYu, Su Jong-
dc.contributor.authorKim, Yoon Jun-
dc.contributor.authorYoon, Jung-Hwan-
dc.date.accessioned2018-05-14T07:52:37Z-
dc.date.available2018-05-14T16:53:33Z-
dc.date.issued2018-03-20-
dc.identifier.citationBMC Cancer, 18(1):307ko_KR
dc.identifier.issn1471-2407-
dc.identifier.urihttps://hdl.handle.net/10371/139757-
dc.description.abstractBackground
Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based model for predicting sorafenib response and overall survival (OS).

Methods
This prospective cohort study included 124 consecutive HCC patients (44 with disease control, 80 with progression) with Child-Pugh class A liver function, who received sorafenib. Potential serum biomarkers (namely, hepatocyte growth factor [HGF], fibroblast growth factor [FGF], vascular endothelial growth factor receptor-1, CD117, and angiopoietin-2) were tested. After identifying independent predictors of tumor response, a risk scoring system for predicting OS was developed and 3-fold internal validation was conducted.

Results
A risk scoring system was developed with six covariates: etiology, platelet count, Barcelona Clinic Liver Cancer stage, protein induced by vitamin K absence-II, HGF, and FGF. When patients were stratified into low-risk (score ≤ 5), intermediate-risk (score 6), and high-risk (score ≥ 7) groups, the model provided good discriminant functions on tumor response (concordance [c]-index, 0.884) and 12-month survival (area under the curve [AUC], 0.825). The median OS was 19.0, 11.2, and 6.1 months in the low-, intermediate-, and high-risk group, respectively (P < 0.001). In internal validation, the model maintained good discriminant functions on tumor response (c-index, 0.825) and 12-month survival (AUC, 0.803), and good calibration functions (all P > 0.05 between expected and observed values).

Conclusions
This new model including serum FGF and HGF showed good performance in predicting the response to sorafenib and survival in patients with advanced HCC.
ko_KR
dc.description.sponsorshipThis work was funded by Doosan Yonkang Foundation (Grant No. 30–2016-0240), Liver Research Foundation of Korea as part of Bio Future Strategies Research Project, and Ewha Womans University research grant (2016). The funding bodies had no role in the design of the study, collection, analysis, and interpretation of data and in writing of the manuscript.ko_KR
dc.language.isoenko_KR
dc.publisherBioMed Centralko_KR
dc.subjectHepatocellular carcinomako_KR
dc.subjectSorafenibko_KR
dc.subjectResponseko_KR
dc.subjectBiomarkerko_KR
dc.subjectPredictionko_KR
dc.titleNovel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김희영-
dc.contributor.AlternativeAuthor이동현-
dc.contributor.AlternativeAuthor이정훈-
dc.contributor.AlternativeAuthor조영윤-
dc.contributor.AlternativeAuthor조은주-
dc.contributor.AlternativeAuthor유수종-
dc.contributor.AlternativeAuthor김윤준-
dc.contributor.AlternativeAuthor윤정환-
dc.identifier.doi10.1186/s12885-018-4211-2-
dc.language.rfc3066en-
dc.rights.holderThe Author(s).-
dc.date.updated2018-03-25T05:30:53Z-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse